08/765026
attachment to
Paper #6

```
*                                                                    *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
FILE 'USPAT' ENTERED AT 15:51:56 ON 29 DEC 1997

  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *                                                                 *
  *              W E L C O M E   T O   T H E                        *
  *         U. S.   P A T E N T   T E X T   F I L E                 *
  *                                                                 *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

=> s polytetrafluoroethylene?
L1        25234 POLYTETRAFLUOROETHYLENE?

=> s l1 and implant?
          52487 IMPLANT?
L2         1420 L1 AND IMPLANT?

=> s l2 and gene therap?
          15178 GENE
          74969 THERAP?
            870 GENE THERAP?
                  (GENE(W)THERAP?)
L3           10 L2 AND GENE THERAP?

=> d l3,1-10,cit
```

1. 5,658,565, Aug. 19, 1997, Inducible nitric oxide synthase gene for treatment of disease; Timothy R. Billiar, et al., 424/93.21, 93.1, 93.2; 435/172.3, 189, 191, 235.1, 320.1; 514/44; 536/23.1, 23.2, 23.5; 935/9, 22, 32, 60 :IMAGE AVAILABLE:

2. 5,626,561, May 6, 1997, **Implantable** containment apparatus for a therapeutical device and method for loading and reloading the device therein; Mark D. Butler, et al., 604/49, 93, 890.1 :IMAGE AVAILABLE:

3. 5,624,840, Apr. 29, 1997, Three-dimensional liver cell and tissue culture system; Brian A. Naughton, et al., 435/395; 424/423; 435/373, 399, 402 :IMAGE AVAILABLE:

4. 5,599,788, Feb. 4, 1997, Method for accelerating skin wound healing with H3 protein; Anthony F. Purchio, et al., 514/2; 424/278.1, 409; 514/12, 885, 886, 887, 944, 945, 946, 947 :IMAGE AVAILABLE:

5. 5,594,136, Jan. 14, 1997, Texaphyrin solid supports and devices; Jonathan L. Sessler, et al., 540/472; 424/9.322; 534/11, 14, 15, 16; 540/145, 474 :IMAGE AVAILABLE:

6. 5,516,681, May 14, 1996, Three-dimensional pancreatic cell and tissue culture system; Gail K. Naughton, et al., 435/353; 424/422, 484, 572; 435/1.1, 1.2, 29, 32, 284.1, 347, 373 :IMAGE AVAILABLE:

7. 5,510,254, Apr. 23, 1996, Three dimensional cell and tissue culture system; Brian A. Naughton, et al., 435/370, 284.1 :IMAGE AVAILABLE:

8. 5,424,208, Jun. 13, 1995, Method for isolating cells from tissue with a composition containing collagenase and chymopapin; Catherine T. Lee, et al., 435/268, 219, 243, 267, 381 :IMAGE AVAILABLE:

9. 5,422,261, Jun. 6, 1995, Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells; Catherine

T. Lee, et al., 435/219; 424/94.2, 94.65, 94.67; 435/212 :IMAGE AVAILABLE:

10. 4,963,489, Oct. 16, 1990, Three-dimensional cell and tissue culture system; Gail K. Naughton, et al., 435/1.1; 424/529, 530, 534, 572, 574; 435/2, 347, 366, 398, 402 :IMAGE AVAILABLE:

=> d kwic,10

5599712

US PAT NO: 4,963,489 :IMAGE AVAILABLE: L3: 10 of 10

5571799

SUMMARY:

BSUM(3)

The resulting cultures have a variety of applications ranging from transplantation or **implantation** in vivo, to screening cytotoxic compounds and pharmaceutical compounds in vitro, and to the production of biologically active molecules in. . .

SUMMARY:

BSUM(14)

The . . . can be grown in the three-dimensional culture system. The resulting cultures have a variety of applications ranging from transplantation or **implantation**, in vivo, of cells grown in the cultures, cytotoxicity testing and screening compounds in vitro, and the design of "bioreactors". . .

DETDESC:

DETD(3)

The . . . variety of applications. For example, for tissues such as skin, glands, etc. the three-dimensional culture itself may be transplanted or **implanted** into a living organism. Alternatively, for diffuse tissues such as bone marrow, the proliferating cells could be isolated from the. . .

DETDESC:

DETD(5)

Fetal . . . particular tissue, organ, or individual. For example, where the three-dimensional culture is to be used for purposes of transplantation or **implantation** in vivo, it may be preferable to obtain the stromal cells and elements from the individual who is to receive the transplant or **implant**. This approach might be especially advantageous where immunological rejection of the transplant and/or graft versus host disease is likely. Moreover,. . .

DETDESC:

DETD(17)

Where the three-dimensional culture is itself to be **implanted** in vivo, it may be preferable to use biodegradable matrices such as PGA, catgut suture material, or gelatin, for example.. . .

DETDESC:

DETD(23)

Again, where the cultured cells are to be used for transplantation or

implantation in vivo it is preferable to obtain the stromal cells from the patient's [redacted]ssues. The growth of cells in[redacted] .

DETDESC:

DETD(37)

The . . . of the invention can be used in a variety of applications. These include but are not limited to transplantation or **implantation** of either the cultured cells obtained from the matrix, or the cultured matrix itself in vivo; screening cytotoxic compounds, allergens,. . . of certain diseases; studying the mechanism by which drugs and/or growth factors operate; diagnosing and monitoring cancer in a patient; **gene therapy**; and the production of biologically active products, to name but a few.

DETDESC:

DETD(38)

For transplantation or **implantation** in vivo, either the cells obtained from the culture or the entire three-dimensional culture could be **implanted**, depending upon the type of tissue involved. For example, three-dimensional bone marrow cultures can be maintained in vitro for long. . .

DETDESC:

DETD(42)

The . . . culture system of the invention may afford a vehicle for introducing genes and gene products in vivo for use in **gene therapies**. For example, using recombinant DNA techniques, a gene for which a patient is deficient could be placed under the control. . . and then clonally expanded in the three-dimensional culture system. The three-dimensional culture which expresses the active gene product, could be **implanted** into an individual who is deficient for that product.

DETDESC:

DETD(43)

The use of the three-dimensional culture in **gene therapy** has a number of advantages. Firstly, since the culture comprises eukaryotic cells, the gene product will be properly expressed and processed in culture to form an active product. Secondly, **gene therapy** techniques are useful only if the number of transfected cells can be substantially enhanced to be of clinical value, relevance,. . .

DETDESC:

DETD(196)

Twenty . . . 6 mm punches were made with a disposable Baker's punch biospy needle, and sub-cuticular suturing was used to hold the **implanted** meshes in place. The rats were closely examined until 12 hours post surgery and then monitored every 24 hours.

DETDESC:

DETD(197)

The areas of mesh **implantation** showed no signs of erythema, swelling, exudate, or fragility. Meshes were removed at 7 days, 14 days, and 21 days. . .

DETDESC:

DETD(198)

Parallel studies have been performed in which meshes with dermal and epidermal components were **implanted** into 10 mm.times.10 mm skin biopsies which were then maintained in culture for 14 days and examined histologically. Similar cell. . .

CLAIMS:

CLMS(7)

7. . . . in which the non-biodegradable material is a polyamide, polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a **polytetrafluoroethylene**, or a nitrocellulose compound.

=> d fro,10

US PAT NO: 4,963,489 :IMAGE AVAILABLE: L3: 10 of 10
DATE ISSUED: Oct. 16, 1990
TITLE: Three-dimensional cell and tissue culture system
INVENTOR: Gail K. Naughton, Groton, VT
Brian A. Naughton, Groton, VT
ASSIGNEE: Marrow-Tech, Inc., La Jolla, CA (U.S. corp.)
APPL-NO: 07/242,096
DATE FILED: Sep. 8, 1988
REL-US-DATA: Continuation-in-part of Ser. No. 38,110, Apr. 14, 1987, which is a continuation-in-part of Ser. No. 36,154, Apr. 3, 1987, Pat. No. 4,721,096, which is a continuation of Ser. No. 853,569, Apr. 18, 1986, abandoned.
INT-CL: :5: C12N 5/00; A01N 1/02
US-CL-ISSUED: 435/240.1, 1, 2, 240.2, 240.23, 240.21; 424/93, 529, 530, 534, 572, 574
US-CL-CURRENT: 435/1.1; 424/529, 530, 534, 572, 574; 435/2, 347, 366, 398, 402
SEARCH-FLD: 435/1, 2, 4, 240.2, 240.243, 240.23, 240.21, 240.1; 424/95, 93
REF-CITED:

U.S. PATENT DOCUMENTS

3,997,396	12/1976	Delente	
4,016,036	4/1977	Green et al.	
4,024,020	5/1977	Weiss	
4,087,327	5/1978	Feder et al.	
4,107,937	8/1978	Chmiel	
4,117,881	10/1978	Williams et al.	
4,135,975	1/1979	Lichtman et al.	
4,144,126	3/1979	Burbridge	
4,228,243	10/1980	Iizuka	
4,280,954	7/1981	Yannas et al.	350/395
4,299,819	11/1981	Eisinger	
4,342,828	8/1982	Takaku et al.	
4,458,678	7/1984	Yannas et al.	
4,481,946	11/1984	Altshuler et al.	
4,485,096	11/1984	Bell	
4,485,097	11/1984	bell	424/95
4,486,188	12/1984	Altshuler et al.	
4,489,710	12/1984	Spitler	
4,520,821	6/1985	Schmidt et al.	
4,546,500	10/1985	Bell	623/1
4,553,272	11/1985	Mears	
4,621,100	11/1986	Lund et al.	

4,642,292	2/1987	Reid et al.	
4,645,669	[redacted]	Reid	
4,703,108	[redacted]	Silver et al.	530/356

FOREIGN PATENT DOCUMENTS

0075904	9/1981	European Patent Office
85109336.9	1/1986	European Patent Office
85303844.6	12/1986	European Patent Office
86306544.7	3/1987	European Patent Office
0081781	11/1981	Japan
60-123884	12/1986	Japan
WO83/04177	12/1983	World Intellectual Property Organization
WO88/03785	6/1988	World Intellectual Property Organization

OTHER PUBLICATIONS

Freshney I. R., 1983. Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., NY, pp. 55-57.
Saber et al., 1981, Mechanisms of Aging and Development, 17:107-117.
Nusgens et al., 1984, Collagen Rel. Res. 4:351-364.
Latsinik et al., 1981, Biol. Abstr. 74:3841.
Gordon et al., 1983, Int. J. Cell Cloning 1:429-39.
Chailakhyan et al., 1984, Biol. Abstr., vol. 80, abstract 28317.
Leighton, J., 1951, J.N.C.I. 12:545-561.
Schneider, H. et al., 1963, Exp. Cell Res. 30:449-459.
Kruse, P. et al., 1965, J. Cell Biol. 27:273-279.
Leighton, J. et al., 1967, Science 155:1259-1261.
Leighton, J. et al., 1968, Cancer Res. 28:286-296.
Elsdale et al., 1972, J. Cell Biol. 54:626-637.
Ansevin, K. et al., 1973, In Vitro 8:483-488.
Sobour, O. et al., 1975, J. Neurosurg 43:742-749.
Douglas, W. H. et al., 1976, In Vitro 12:373-381.
Ebendal, E., 1976, Exp. Cell Res. 98:159-169.
Emerman, J., et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:4466-4470.
Bell, E. et al., 1979, PNAS 76:1274-1278.
Lindsay, R., 1979, Naturo 282:80-82.
Reid, L. et al., 1979, 58:263-278.
Yang, L. et al., 1979, Proc. Natl. Acad. Sci. U.S.A. 76:3401-3405.
Douglas, W. et al., 1980, In Vitro 16:306-312.
Folkman, J. et al., Nature 288:551-555.
Vlodavsky, D. et al., 1980, Cell 19:607-616.
Yang, J. et al., 1980, PNAS 77:2088-2092.
Yang, J. et al. 1981, Cancer Res 41:1021-1027.
Thuroff, et al., 1983, Urology 21:155-158.
Daniels, E. and Moore, 1969, Anat. Res. 163:174.
Daniels, E., 1975, Anat. Rec. 181:341.
Dexter, T. M. et al., 1976, in "Methods in Cell Biology", editor D. M. Prescott, pp. 387-405, Academic Press, N. Y.
Dexter, T. M. et al., 1976, J. Cell. Physiol. 91:335-344.
Blackburn, M. et al., 1977, Br. J. Haematology 37:337.
Dexter, T. M., 1979, Acta. Haemat, 62:299-305.
Daniels, E., 1978, Anat. Rec. 190:376.
Moore, M. A. S. et al., 1979, Blood Cells 5:297-311.
Reimann, J. et al., 1979, Exp. Hematol 7:52-58.
Daniels, E., 1980, Exp. Hematol. 8:157-165.
Gartner, S. et al., 1980, Proc. Natl. Acad Sci., 77:4756-4759.
Hocking, W. G. et al., 1980, in "Biology of Bone Marrow Transplantation", edited by R. B. Gale, et al., pp. 431-442, Academic Press, N.Y.
Daniels, 1981, Exp. Hematol. 9:697-710.
Daniels, E., 1981, Anat. Rec. 199-63A.
Coulombel et al., 1983, Blood 62:291-297.
Daniels, E., 1983, RES: Journal of Recticuloendothelial Society 33:457-465.
Dexter, T. et al., 1984, in "Long-Term Bone Marrow" editor Wright et al.,

pp. 57-96, Alan R. Liss.
Greenberger, J. S. [redacted] in "Long-Term Bone Marrow Cu[redacted]e", editor D. Wright, pp. 119-[redacted], Alan R. Liss, N.Y.
Phillips, R. A., 1984, in "Long-Term Bone Marrow Culture", editor D. Wright, pp. 309-321, Alan R. Liss, Inc., N. Y.
Chang, J., et al., 1986, The Lancet, pp. 294-295.
Brockbank, K. G. M., et al., 1986, Exp. Hematol. 14:386-394.
McMillen et al., 1986, J. Surg. Res. 40:193-197.
Naughton et al., 1986, Blood 68:149a.
Page et al., 1986, Exp. Hematol. 14:719-723.
Yuen et al., 1986, Exp. Hematol. 14:771-775.
Hunt et al., 1987, Cell, 48:996-1007.
Rennick et al., 1987, Blood 69:682-691.
Whitlock et al., 1987, Cell, 48:1009-1021.
E. Daniels, 1977, Anat. Rec. 187:562.
Corin, N. C. et al., 1978, Blood 51:2157-265.
Ritz et al., 1982, The Lancet, Jul. 10, 1982, pp. 60-63.
Van De Ouweland, F. et al., 1982, Cryobiology 19:292-298.
Parkman, 1986, Science 232:1373-1378.
Green et al., 1978, Science 200:1385-1388.
Bell, E. et al., 1979, Proc. Natl. Acad. Sci. U.S.A. 76:1274-1278.
Green, H. et al., 1979, Proc. Natl. Acad. Sci. U.S.A. 76:5665-5668.
Yannas, I. et al., 1980, J. Biomedical Res. 14:107-131.
Bell, E. et al., 1981, Science 211:1052-1054.
Yannas et al., 1982, Science 215:174-176.
Bell, E. et al., 1983, J. Invest. Dermatol. 81:2.sub.s -10.sub.s.
Kao, J. et al., 1983, Toxicol. and Appl. Pharmacol. 68:206-217, (1983).
Gallico et al., 1984, N. Engl. J. Med. 311:448-451.
Pittelkow et al., 1986, Mayo Clin. Proc. 61:771-777.
Boyce, J., et al., 1988, Surgery 421-431.
Michalopoulos, G. and Pitot, H., 1975, Fed. Proc. 34:826.
Michalopoulos, G., Sattler, G., O'Connor, L., and Savage, R. and Bonney, R., 1978, Exp. Cell Res. 114:307-315.
Sirica, A., Ricahards, W., Tsukada, Y., Sattler, C., and Pitot, H., 1979, Proc. Natl. Acad. Sci., U.S.A. 76:283-287.
Sirica, A., Hwang, C., Sattler, G. and Pitot, H., 1980, Cancer Res. 40:3259-3267.

ART-UNIT: 184
PRIM-EXMR: Charles F. Warren
ASST-EXMR: Christopher Low
LEGAL-REP: Pennie & Edmonds

ABSTRACT:
The present invention relates to a three-dimensional cell culture system which can be used to culture a variety of different cells and tissues in vitro for prolonged periods of time. In accordance with the invention, cells derived from a desired tissue are inoculated and grown on a pre-established stromal support matrix. The stromal support matrix comprises stromal cells, such as fibroblasts, grown to subconfluence on a three-dimensional matrix. Stromal cells may also include other cells found in loose connective tissue such as endothelial cells, macrophages/monocytes, adipocytes, pericytes, reticular cells found in bone marrow stroma, etc. The stromal matrix provides the support, growth factors, and regulatory factors necessary to sustain long-term active proliferation of cells in culture. When grown in this three-dimensional system, the proliferating cells mature and segregate properly to form components of adult tissues analogous to counterparts found in vivo.

10 Claims, 10 Drawing Figures

=> d clms,10

US PAT NO: 4,963,489 :IMAGE AVAILABLE: L3: 10 of 10

CLAIMS:

CLMS(1)

What is claimed i[redacted]

1. A living stromal tissue prepared in vitro, comprising stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material formed into a three dimensional structure having interstitial spaces bridged by the stromal cells.

CLMS(2)

2. The living stromal tissue of claim 1 in which the stromal cells are fibroblasts.

CLMS(3)

3. The living stromal tissue of claim 1 in which the stromal cells are a combination of fibroblasts and endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells or adipocytes.

CLMS(4)

4. The living stromal tissue of claim 1 in which the framework is composed of a biodegradable material.

CLMS(5)

5. The living stromal tissue of claim 4 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.

CLMS(6)

6. The living stromal tissue of claim 1 in which the framework is composed of a non-biodegradable material.

CLMS(7)

7. The living stromal tissue of claim 6 in which the non-biodegradable material is a polyamide, polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a **polytetrafluoroethylene**, or a nitrocellulose compound.

CLMS(8)

8. The living stromal tissue of claims 4, 5, 6 or 7 in which the framework is pre-coated with collagen.

CLMS(9)

9. The living stromal tissue of claims 1, 2, 3, 4, 5, 6, or 7 in which the framework is a mesh.

CLMS(10)

10. The living stromal tissue of claim 8 in which the framework is a mesh.